| NF-κB, an active player in human cancers Y Xia, S Shen, IM Verma Cancer immunology research 2 (9), 823-830, 2014 | 1167 | 2014 |
| Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10 ML Maeder, M Stefanidakis, CJ Wilson, R Baral, LA Barrera, ... Nature medicine 25 (2), 229-233, 2019 | 616 | 2019 |
| Characterization of Staphylococcus aureus Cas9: a smaller Cas9 for all-in-one adeno-associated virus delivery and paired nickase applications AE Friedland, R Baral, P Singhal, K Loveluck, S Shen, M Sanchez, ... Genome biology 16, 1-10, 2015 | 340 | 2015 |
| Terminal N-linked galactose is the primary receptor for adeno-associated virus 9 S Shen, KD Bryant, SM Brown, SH Randell, A Asokan Journal of Biological Chemistry 286 (15), 13532-13540, 2011 | 316 | 2011 |
| Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer N Pulicherla, S Shen, S Yadav, K Debbink, L Govindasamy, ... Molecular Therapy 19 (6), 1070-1078, 2011 | 275 | 2011 |
| Delivery and specificity of CRISPR/Cas9 genome editing technologies for human gene therapy JL Gori, PD Hsu, ML Maeder, S Shen, GG Welstead, D Bumcrot Human gene therapy 26 (7), 443-451, 2015 | 249 | 2015 |
| CRISPR/CAS-related methods and compositions for treating leber's congenital amaurosis 10 (LCA10) ML Maeder, DA Bumcrot, S Shen US Patent 9,938,521, 2018 | 119 | 2018 |
| Engraftment of a galactose receptor footprint onto adeno-associated viral capsids improves transduction efficiency S Shen, ED Horowitz, AN Troupes, SM Brown, N Pulicherla, RJ Samulski, ... Journal of Biological Chemistry 288 (40), 28814-28823, 2013 | 108 | 2013 |
| Glycan binding avidity determines the systemic fate of adeno-associated virus type 9 S Shen, KD Bryant, J Sun, SM Brown, A Troupes, N Pulicherla, A Asokan Journal of virology 86 (19), 10408-10417, 2012 | 65 | 2012 |
| Amelioration of alpha-1 antitrypsin deficiency diseases with genome editing in transgenic mice S Shen, ME Sanchez, K Blomenkamp, EM Corcoran, E Marco, CJ Yudkoff, ... Human Gene Therapy 29 (8), 861-873, 2018 | 56 | 2018 |
| A combination therapy for KRAS-driven lung adenocarcinomas using lipophilic bisphosphonates and rapamycin Y Xia, YL Liu, Y Xie, W Zhu, F Guerra, S Shen, N Yeddula, W Fischer, ... Science translational medicine 6 (263), 263ra161-263ra161, 2014 | 53 | 2014 |
| Functional analysis of the putative integrin recognition motif on adeno-associated virus 9 S Shen, GE Berry, RMC Rivera, RY Cheung, AN Troupes, SM Brown, ... Journal of Biological Chemistry 290 (3), 1496-1504, 2015 | 50 | 2015 |
| Multiple roles for sialylated glycans in determining the cardiopulmonary tropism of adeno-associated virus 4 S Shen, AN Troupes, N Pulicherla, A Asokan Journal of virology 87 (24), 13206-13213, 2013 | 48 | 2013 |
| 687. Therapeutic correction of an LCA-causing splice defect in the CEP290 gene by CRISPR/Cas-mediated genome editing ML Maeder, S Shen, ER Burnight, S Gloskowski, R Mepani, AE Friedland, ... Molecular therapy 23, S273-S274, 2015 | 24 | 2015 |
| 124. Therapeutic correction of an LCA-causing splice defect in the CEP290 gene by CRISPR/Cas-mediated gene editing ML Maeder, R Mepani, S Gloskowski, M Skor, MK Collins, S Shen, ... Molecular Therapy 24, S51-S52, 2016 | 16 | 2016 |
| CRISPR/CAS-related methods and compositions for treating Leber's Congenital Amaurosis 10 (LCA10) ML Maeder, DA Bumcrot, S Shen US Patent 10,253,312, 2019 | 6 | 2019 |
| Methods and compositions for targeted gene transfer A Asokan, G Murlidharan, S Shen US Patent 10,907,176, 2021 | 5 | 2021 |
| Compositions and methods for treating CEP290-associated disease ML Maeder, RJ Mepani, DA Bumcrot, S Shen, M Stefanidakis US Patent 11,339,437, 2022 | 2 | 2022 |
| Systems and methods for treating alpha 1-antitrypsin (A1AT) deficiency S Shen, P O'donnell, M Sanchez US Patent 11,512,311, 2022 | 1 | 2022 |
| Treatment of herpetic keratitis with CRISPR/Cas9 gene editing in a rabbit disease model S Shen, CM Owens, H Chao, CJ Yudkoff, B Diner, R Fusco, D Tabbaa, ... MOLECULAR THERAPY 26 (5), 128-128, 2018 | 1 | 2018 |
Aravind AsokanDuke UniversityVerified email at duke.edu
